Dr Evanthia Galanis | Professor, Chair Molecular Medicine
Mayo Clinic

Dr Evanthia Galanis, Professor, Chair Molecular Medicine, Mayo Clinic

Evanthia Galanis, M.D., has a long-standing interest in developing novel therapeutic approaches for cancer treatment. The focus of her laboratory is to develop and optimize novel virotherapy approaches with special emphasis on paramyxoviruses. A number of different strategies are tested, including use of therapeutic transgenes; trackable markers; combinations with small molecules, cytotoxic agents and radiation therapy; re-targeting of viral strains against tumor-specific antigens; development of novel viral delivery approaches; and exploration of immunomodulatory methods to modify humoral and innate immunity as a means of optimizing virotherapy efficacy. A significant impetus for Dr. Galanis' research has been the translation of laboratory advances into clinical trials of novel virotherapeutics and small molecules in cancer patients. She has served as the principal investigator in multiple phase I and II virotherapy trials in different solid tumors (ovarian cancer, glioblastoma, renal cell carcinoma, colorectal cancer, melanoma, hepatocellular carcinoma), and she has spearheaded the clinical translation of measles derivatives and their first human testing in patients with ovarian cancer or brain tumors, as well as first human use of live cell carriers for oncolytic virus delivery. She has also conducted multiple cooperative group phase II and randomized studies of small molecules and anti-angiogenesis agents in the treatment of glioblastoma through the North Central Cancer Treatment Group and the Alliance for Clinical Trials in Oncology. In addition, Dr. Galanis has a special research interest in clinical trial endpoints and innovative trial designs in neuro-oncology. Her work has been supported by the National Cancer Institute, and she has been involved in several Mayo Clinic Specialized Programs of Research Excellence (SPOREs), including the Brain Cancer, Ovarian Cancer and Breast Cancer SPOREs.

Appearances:



December 3 - Main Congress Day 1 @ 15:10

Panel: Novel approaches for the delivery of oncolytic viruses and genes

last published: 20/Aug/19 15:45 GMT

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com